EXACT Sciences Price Target Raised to $23.00 (EXAS)
Equities researchers at Canaccord Genuity upped their price objective on shares of EXACT Sciences (NASDAQ:EXAS) from $21.00 to $23.00 in a research report issued on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective suggests a potential upside of 9.32% from the stock’s previous close.
EXACT Sciences (NASDAQ:EXAS) opened at 21.04 on Tuesday. EXACT Sciences has a 52 week low of $9.53 and a 52 week high of $21.45. The stock has a 50-day moving average of $16.91 and a 200-day moving average of $14.60. The company’s market cap is $1.745 billion.
EXACT Sciences (NASDAQ:EXAS) last released its earnings data on Tuesday, July 22nd. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.
A number of other firms have also recently commented on EXAS. Analysts at Benchmark Co. upgraded shares of EXACT Sciences to a “buy” rating in a research note on Tuesday, August 12th. Separately, analysts at Jefferies Group raised their price target on shares of EXACT Sciences from $18.00 to $20.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Finally, analysts at Maxim Group reiterated a “sell” rating on shares of EXACT Sciences in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. EXACT Sciences currently has an average rating of “Hold” and an average target price of $20.00.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.